Vor Bio (Nasdaq: VOR) granted inducement equity awards to 7 newly hired employees under its 2023 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Awards include stock options for 71,200 shares at $18.39 per share and RSUs for 15,150 shares, each vesting over four years.
New equity awards may incrementally dilute existing shareholders
News Market Reaction – VOR
-2.38%
64 alerts
-2.38%News Effect
+15.8%Peak in 50 min
-$29MValuation Impact
$1.20BMarket Cap
0.7xRel. Volume
On the day this news was published, VOR declined 2.38%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +15.8% during that session.
Our momentum scanner triggered 64 alerts that day, indicating high trading interest and price volatility.
This price movement removed approximately $29M from the company's valuation, bringing the market cap to $1.20B at that time.
New-hire equity awards covering 71,200 options and 15,150 RSUs under the Inducement Plan modestly ad...
Analysis
New-hire equity awards covering 71,200 options and 15,150 RSUs under the Inducement Plan modestly add to potential dilution. With an effective resale shelf and elevated short interest, investors may watch how staffing growth translates into clinical and regulatory execution.
Key Figures
Stock options granted:71,200 sharesRSUs granted:15,150 sharesNewly hired employees:7 employees+5 more
8 metrics
Stock options granted71,200 sharesJuly 1, 2026 inducement awards to new employees
RSUs granted15,150 sharesJuly 1, 2026 inducement awards to new employees
Newly hired employees7 employeesRecipients of inducement stock options and RSUs
Option term10 yearsTerm of inducement stock options
Option exercise price$18.39 per shareEqual to closing price on July 1, 2026 grant date
Option vesting period4 years25% after 12 months, remainder monthly over 36 months
RSU vesting period4 years25% after 12 months, remainder quarterly over 36 months
Initial cliff vesting25% after 12 monthsApplies to both options and RSUs, employment-contingent
"were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"and restricted stock units (“RSUs”) representing the right to receive an aggregate of 15,150 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise pricefinancial
"The stock options have a ten-year term, and an exercise price of $18.39 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement planfinancial
"were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”)"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 15,150 shares of Vor Bio’s common stock to 7 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term, and an exercise price of $18.39 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options.The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates.The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
FAQ
What inducement equity grants did Vor Bio (Nasdaq: VOR) announce on July 2, 2026?
Vor Bio announced stock option and RSU inducement grants to 7 new employees. According to Vor Bio, these include options for 71,200 shares and RSUs for 15,150 shares of common stock, granted under the 2023 Inducement Plan.
How many stock options and RSUs did Vor Bio grant to new employees in July 2026?
Vor Bio granted 71,200 stock options and 15,150 RSUs as inducement awards. According to Vor Bio, these equity grants are for 7 newly hired employees and are subject to the 2023 Inducement Plan and related award agreements.
What are the vesting terms of Vor Bio’s July 2026 inducement stock options (VOR)?
Vor Bio’s inducement stock options vest over four years. According to Vor Bio, 25% of the shares vest after 12 months, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued employment.
What is the exercise price and term of Vor Bio’s new inducement stock options?
The inducement stock options have a ten-year term and a $18.39 exercise price. According to Vor Bio, this price equals the closing price of its common stock on the July 1, 2026 grant date, aligning awards with market value.
How do Vor Bio’s July 2026 inducement RSUs for VOR employees vest?
Vor Bio’s inducement RSUs vest over four years. According to Vor Bio, 25% of the RSU shares vest after 12 months, with the remaining 75% vesting in equal quarterly installments over the next 36 months, subject to continued employment.
Under which plan were Vor Bio’s July 2026 inducement equity awards granted?
The inducement equity awards were granted under the 2023 Inducement Plan. According to Vor Bio, both the stock options and RSUs are issued as material inducements to employment, in line with Nasdaq Listing Rule 5635(c)(4), and follow related award agreements.
